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Modified nucleic acids, also called xeno nucleic acids (XNAs), offer a variety of advantages for biotechnological
applications and address some of the limitations of first-generation nucleic acid therapeutics. Indeed, several
therapeutics based on modified nucleic acids have recently been approved and many more are under clinical
evaluation. XNAs can provide increased biostability and furthermore are now increasingly amenable to in vitro
evolution, accelerating lead discovery. Here, we review the most recent discoveries in this dynamic field with a
focus on progress in the enzymatic replication and functional exploration of XNAs.Nucleic acids: natural and expanded functions
A heritable genetic system is a defining requirement for
life. The natural nucleic acids, DNA and RNA, are ex-
quisitely suited to store and propagate genetic informa-
tion with sufficient stability and fidelity to support large
genomes but also the flexibility to enable evolution. Nu-
cleic acids are unique among biopolymers in that both
accessible information and functional capacity coexist in
a single molecule. Thus, function can be evolved at the
molecular level yielding nucleic acid-based ligands and
enzymes. In addition, nucleic acids fold through predict-
able and (to a large extent) programmable interactions,
are highly water-soluble, and can be easily denatured
and refolded. These advantages underpin their manifold
uses in biotechnology, diagnostics, therapeutics, nano-
technology, material science, synthetic biology, and data
storage.
The last four decades have seen the rise of nucleic
acids as therapeutics [1], primarily in the form of anti-
sense oligonucleotides (ASOs) [2], small interfering
RNAs (siRNAs) [3], aptamers [4–6], microRNAs [7],
mRNAs [8], and gene-editing guides [9]. Nucleic acids© The Author(s). 2020 Open Access This artic
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vention (e.g., direct protein expression or specific and
programmable modulation of gene expression) that can-
not be easily accessed by other biologics or small mol-
ecule drugs. However, several challenges have thus far
prevented nucleic acids from reaching their full potential
as medicines including poor chemical and biological
stability and narrow chemical diversity.
To address these limitations, DNA and RNA analogues
have been developed and evaluated for their ability to
serve as useful biomaterials or functional molecules, en-
code genetic information, and support evolution. These
synthetic genetic polymers, broadly termed xeno nucleic
acids (XNAs), exhibit modified backbones, sugars, or
nucleobases, and even novel bases or base pairs [10, 11].
While natural nucleic acids may also be modified to
modulate their function in vivo (e.g., post-synthetic epi-
genetic modifications) [12–17], we constrain ourselves
here to a discussion of nucleic acid congeners not found
in nature. We do, however, consider certain modifica-
tions that occur sporadically in natural oligonucleotides,
such as 2′OMe or C5 pyrimidine modifications, to be
XNAs in the case of fully (or heavily) substituted oligo-
nucleotides, the likes of which are not found in biology.
Several new and prominent XNA chemistries are shown
in Fig. 1. One attractive feature of XNAs is their gener-
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Fig. 1 (See legend on next page.)
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Fig. 1 The chemical diversity of XNAs. XNAs are often categorized by the component of the nucleotide (sugar, backbone, or base) carrying a
modification. Shown here are XNAs discussed in this review, including both those of medical and historical relevance as well as several newly
described chemistries. 2′F, 2′-fluoro; 2′OMe, 2′-O-methyl; LNA, locked nucleic acid; FANA, 2′-fluoro arabinose nucleic acid; HNA, hexitol nucleic acid;
2′MOE, 2′-O-methoxyethyl; ribuloNA, (1′-3′)-β-L-ribulo nucleic acid; TNA, α-L-threose nucleic acid; tPhoNA, 3′-2′ phosphonomethyl-threosyl nucleic
acid; dXNA, 2′-deoxyxylonucleic acid; PS, phosphorothioate; phNA, alkyl phosphonate nucleic acid; PNA, peptide nucleic acid
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hydrophobic groups) can also yield improved properties
and functionalities such as new structural motifs and en-
hanced target binding [21–24]. While a wide range of
XNAs have been synthesized at the chemical level,
representing a rich palette to draw from, their functional
potential and usage is only just beginning to be probed.
Here, we explore recent discoveries in the enzymatic
synthesis and functional exploration of XNAs with a
view towards therapeutic applications.
Expanding the chemistry of nucleic acids
Advances in nucleic acid chemistry have enabled the de-
velopment of XNAs with improved base-pairing stability
over natural nucleic acids as well as enhanced activity in
the context of living tissues, leading to several FDA ap-
proved nucleic acid therapeutics [25]. Research con-
tinues apace to identify novel chemistries with increased
potency, bioavailability, stability, decreased toxicity, and
minimal off-target effects.
An interesting development in this context is the dis-
covery that mixed backbone chemistries can display
novel emergent properties. For example, Krishnamurthy
and colleagues probed the ability of XNA-RNA chimeric
oligonucleotides to hybridize with their natural nucleic
acid counterparts and found that the otherwise non-
pairing ribuloNA can be interspersed with RNA or DNA
building blocks to yield oligonucleotides with compar-
able or higher duplex thermal stability than natural sys-
tems and tuneable base-pairing properties [26]. The
authors suggest that such a system could be used to
mimic natural base-pairing rules with a reduced number
of bases, storing information in the sugar in place of the
GC base pair.
Similarly, the recent discovery that smaller “skinny”
(pyrimidine-like) and larger “fat” (purine-like) base pairs
can form stable helices challenges conventional assump-
tions of nucleic acid structure [27]. While the novel base
pairs did not lend stability when interspersed in a nat-
ural oligonucleotide duplex, fully skinny or fat duplexes
showed increased thermal stability over the correspond-
ing natural duplexes.
In another example of XNAs reshaping classical as-
sumptions [28], enzymatic synthesis of phosphonate nu-
cleic acid (phNA), in which the negatively charged non-
bridging oxygen of the phosphodiester linkage is re-
placed by an uncharged alkyl group, has enabled thedemonstration of genetic function in an uncharged back-
bone chemistry for the first time as well as in vitro evo-
lution of phNA aptamers [29].
As certain individual modifications become easier to
synthesize and their unique properties better under-
stood, combining two or more of these known modifica-
tions to sugars, backbones, and bases will further push
the boundaries of chemical diversity in XNAs [30–35].
The development of ever more diverse chemistries
raises the question: how much of what we know about
natural nucleic acids translates to XNA? To what extent
can we borrow design strategies from natural nucleic
acids in order to rapidly develop useful new XNA chem-
istries? Some design rules, such as the ability of certain
sequence motifs to form G-quadruplexes, have been
shown to translate to TNA [36] and FANA [37]. How-
ever, the generality of such parallels remains to be explored.
Templated synthesis of non-natural nucleic acids
The phosphoramidite approach to solid-phase DNA syn-
thesis [38, 39] developed in the early 1980s led to the main-
stream use of synthetic DNA in a myriad of applications.
Similarly, improvements in the synthesis of XNAs can be
expected to increase their usage and unlock new applica-
tions in the coming decades. XNA synthesis can be broadly
divided into enzymatic and non-enzymatic approaches.
Some widely used XNAs (e.g., 2′OMe, LNA, PS, 2′MOE)
can be chemically synthesized, although yields of even the
most synthetically accessible XNAs are limited to around
150 bp [40]. For other XNA chemistries, no reliable solid-
phase synthetic route is known [41]. Furthermore, solid-
phase synthesis depends on explicit knowledge of the se-
quence being synthesized. In contrast, templated synthesis
enables general information transfer and is essential for the
evolution of functional oligonucleotides.
Non-enzymatic templated synthesis
Non-enzymatic templated synthesis traditionally uses acti-
vated nucleotides or short oligonucleotide building blocks
that self-organize on a template via base-paring interac-
tions and react to polymerize. Such template copying, pio-
neered in the 1970s [42–44], has been extended to several
XNA chemistries [45–53], often in the context of prebiotic
nucleic acid replication. For example, systems for tem-
plated replication of PNA pentamers [54, 55] using reduc-
tive amination are efficient enough to permit model
selection experiments [56]. Similar strategies have also
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catalyzed click ligation of oligonucleotides [57, 58] and by
phosphoramidate ligation [59], and the resulting back-
bones have shown some biocompatibility [60]. In an inter-
esting extension of this work, nucleic acid templates have
also been used to organize chemical entities by proximity
for programmed reactions [61–63]. In particular, the Liu
group has extended such templated synthesis approaches
to chemically ligate diverse non-nucleic acid entities in
precise sequences defined by a DNA template [64]. Such
templated chemical syntheses allow increasingly divergent
chemistries to be synthesized and replicated without con-
straining polymer diversity by the ability of its constituent
monomers to serve as substrates for polymerases or other
nucleic acid-modifying enzymes.
Enzymatic ligation and modification of XNAs
Several DNA ligases have been shown to accept non-
natural substrates and have been used alone or in con-
junction with XNA polymerases to synthesize XNA oli-
gonucleotides. Much like the aforementioned chemical
ligation strategies, enzymatic ligation of pre-organized
oligomers on a template allows for positioning of modi-
fied nucleotides, including multiple different modifica-
tions, at defined loci. It has recently been shown that
several commercially available ligases can catalyze
ligation of XNA substrates including 2′OMe, HNA,
LNA, TNA, and FANA [41, 65]. Moreover, rational
design and molecular modeling approaches have now
resulted in the first XNA-templated XNA ligase [66].
The Liu and Hili groups have also worked extensively
with ligase-mediated synthesis of modified DNA from
diversely functionalized DNA 3- or 5-mers [67, 68],
allowing a great variety of modifications, including
hydrophobic, aliphatic, aromatic, acid, and basic moi-
eties, to be incorporated using these short “quasico-
dons.” In agreement with results obtained with
SOMAmer (Slow Off-rate Modified Aptamer) selections
[22], they find that functionalization with nonpolar moi-
eties appears to promote faster selection convergence
and stronger aptamer binding [21]. Incorporating chem-
ical diversity beyond that found in proteins (e.g., haloge-
nated residues), the group isolated high affinity aptamers
against PCSK9 and interleukin-6 [69]. The above strategies
encapsulate the paradigm of leveraging the unique proper-
ties of nucleic acids (i.e., encoded synthesis, evolvability)
coupled with an expanded set of chemical substituents to
create functional molecules with therapeutic potential.
Polymerase synthesis of XNAs
Enzymatic polymerization of nucleic acids is orders of
magnitude faster and more accurate than chemical copy-
ing or synthesis and is now being pursued for next-
generation DNA oligonucleotide synthesis [70, 71], witha view to supersede phosphoramidite technology. Similarly,
enzymatic XNA synthesis may facilitate production of
XNA oligonucleotides. XNAs with chemically conservative
modifications are accepted as substrates by natural poly-
merases, while engineering of polymerases to accept a
broader range of XNA substrates has also met with success
[72, 73]. Indeed, some polymerases have proven highly
adaptable to new substrates. Thermophilic B-family poly-
merases, especially those from Pyrococcus and Thermococ-
cus genera, have proven especially amenable to engineering
for XNA substrates [33, 74–81]. This functional plasticity
may be aided by high thermostability, which promotes
greater tolerance for mutations that would otherwise be ex-
cessively destabilizing. However, A-family [82–90] and
mesophilic polymerases such as Phi29 [91, 92] as well as
RNA polymerases [93–97] have also been engineered to
accept XNA substrates with success (Table 1). However,
the efficiency, fidelity, and kinetics of engineered polymer-
ases on XNA substrates are usually compromised relative
to the native enzymes and natural substrates. Often, “for-
cing” conditions (e.g., superstoichiometric polymerase con-
centrations or the presence of Mn2+, which in turn reduces
fidelity) are needed to boost synthetic yields [106].
Capitalizing on the promiscuity of natural polymerases
It is perhaps remarkable that natural polymerases can
incorporate modified nucleotides at all, given their need
for stringent substrate specificity and accuracy. However,
at some positions in the nucleotide, modifications are
readily tolerated. For example, modifications at the C5
position of pyrimidines and C7 position of N7-deaza-
purines project into the duplex’s major groove and do
not interfere with Watson-Crick base pairing. Therefore,
even bulky adducts at these positions are generally well
tolerated by polymerases [22, 107–112]. Enzymatic syn-
thesis of nucleotides with reactive groups (e.g., for
copper-catalyzed click chemistry) at these positions can
allow elaborate post-synthetic modifications [113–117].
The plasticity of polymerases has also allowed researchers
to carry out wholesale replacement of natural bases with
close chemical analogues [118, 119]. In some cases, synthe-
sis is efficient enough to produce modified PCR products of
up to 1.5 kb [119]. Moreover, entirely new unnatural base
pairs (UBPs) have been developed based on novel hydrogen
bonding patterns [105, 120], hydrophobicity [121, 122], and
shape complementarity [123–125]. These UBPs can be rep-
licated by engineered and natural polymerases, demonstrat-
ing successful expansion of the genetic code, and recently
achieving information encoding in an unprecedented eight-
letter genetic alphabet [120].
XNA synthesis in vivo
The synthesis and replication of XNAs in vivo represents
an important frontier in XNA research towards aims
Table 1 Polymerase-mediated synthesis of XNAs
Pol Family Polymerase Novel Activity Ref.
Pol A Taq
Tth
Pol θ
2’F RNA
2’OME RNA
2’-azido RNA
[83, 84, 87, 88, 90, 98]
Pol B Tgo
KOD
9°N
Pfu
phi29
CeNA
LNA
phNA
HNA
FANA
CyDNA
2’F RNA
ANA
TNA
2’azido RNA
tPhoNA
[29, 33, 75, 78, 81, 82, 92]
Pol Y (D-aa) Dpo4 L-DNA [99–101]
Pol X (D-aa) ASFV pol L-DNA
L-RNA
[102]
RNAP T7 RNAP
Syn5
2’F RNA
2’OMe RNA
Ds-Pa UBP
[95, 97, 103, 104]
RT HIV-RT pyDAD-puADA UBP [105]
Natural and engineered polymerases across of wide range of families have been used to synthesize unnatural nucleic acids. Polymerases are shown as space-
filling models with primer shown in blue and templates shown in red. PDB codes are 4BWJ (Taq), 5OMF (KOD), 4G3I (Dpo4), 5HRF (ASFV), 1H38 (T7 RNAP), and
6HAK (HIV RT)
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genetic orthogonality for “firewalling” synthetic biology.
To this end, complete replacement of cytidine and/or
thymidine with 5-substituted pyrimidine analogues in
bacterial genomes has now been achieved by careful
metabolic engineering and evolution [126–129].
Remarkably, Romesberg and colleagues have been able
to engineer E. coli strains with the capacity to replicate
and maintain their unnatural NaM–TPT3 base pair in
both plasmid [130] and genomic [131] contexts. To
achieve this, they engineered a nucleoside triphosphate
transporter [132], invoked Cas9 to degrade sequences
having lost the UBP, and made several tweaks to the E.
coli DNA synthesis and repair machinery. They further
demonstrated the compatibility of the UBP with transla-
tion machinery to site-specifically encode unnatural
amino acids [133, 134]. Further semi-synthetic organisms
with substituted genomes or the ability to propagate UBPs
will likely follow these early successes [135, 136].
Directed evolution for XNA polymerase engineering
While base modifications and even completely new base
pairs are tolerated by natural polymerases to varying ex-
tents, modifications to the sugar and backbone generally
prove more challenging, especially at full substitution.
To improve activity with such unnatural substrates,
polymerase engineering approaches, ranging from ra-
tional engineering driven by structural insights or com-
putational analysis to screening and directed evolution,
are often employed. Among these, emulsion-based
methods and phage display have been especially useful
[137, 138].
A range of directed evolution strategies have been
employed in the field. Compartmentalized self-
replication (CSR) [139–141] challenges polymerases to
PCR amplify their own gene inside an emulsion com-
partment. The exponential enrichment of highly active
clones, as opposed to simple partitioning of active vari-
ants, makes CSR a powerful method. However, it places
stringent demands on polymerase performance, which
are somewhat relieved in short-patch CSR (spCSR) [85]
where amplification is confined to only a short section
of the polymerase gene. Nested CSR allows selection of
sequences or features not present in the polymerase
gene itself (e.g., novel base pairs, reverse transcription of
XNA templates) by using out-nesting primers with these
features during the CSR amplification step [79, 86]. A
further extension called compartmentalized partnered
replication (CPR) can be used to select for enzymatic
activities other than nucleic acid polymerization by con-
straining the selectable PCR reaction by the fitness of a
partner gene [86, 142]. Recently, CSR has also been
adapted for isothermal amplification reactions (iCSR),
both at high temperatures [143] and at lowertemperatures for evolution of non-thermostable enzymes
[91]. Compartmentalized self-tagging (CST) [144] allows
selection for much more difficult substrates or condi-
tions; selection is based on a primer extension templated
by the encoding plasmid. The biotinylated primer along
with any plasmids that have been “captured” by suffi-
cient primer extension are partitioned on streptavidin
beads. CST has yielded polymerases for a range of XNAs
[78], most recently for dxNA [145]. In contrast to bulk
emulsification methods, microfluidic devices have been
used to generate highly homogeneous emulsion droplets,
enhancing the ability to accurately distinguish small in-
cremental improvements important in stepwise selec-
tions [146, 147]. Another directed evolution strategy is
phage display, whereby polymerases displayed on phage
particles are challenged to extend a primer with separ-
able (e.g., biotinylated) nucleotides [80, 89, 148]. In a
notable recent use of phage display for polymerase evo-
lution, Chen et al. identified several Taq variants capable
of synthesizing and reverse transcribing 2′OMe RNA
[88], an XNA of particular interest for therapeutics due
to its high biostability and nuclease resistance.
Rational engineering of XNA polymerases: structural
insights
Polymerases make many key contacts with the incoming
nucleotide triphosphate and primer strand during the
catalytic cycle [149]. Structures of polymerases in com-
plex with modified substrates may therefore aid in both
rational engineering and retrospective understanding of
XNA polymerases. Recently, Kropp et al. solved ternary
structures of KlenTaq polymerase with a C5-modified
cytidine at each of six successive positions [150] in the
catalysis cycle, recapitulating the movement of the modi-
fied substrate through the polymerase’s active site and
revealing a surprising level of flexibility in both the
modified nucleotide and the interacting polymerase resi-
dues to accommodate the modification.
Further structural insight into XNA polymerization
has been reported by Singh et al. [151] with structures
of an engineered KlenTaq in a binary pre-incorporation
and a ternary post-incorporation complex with the un-
natural base pair dZ:dP. Although none of the mutated
amino acids are in direct contact with primer, template,
or incoming dZTP, the structure suggests that increased
flexibility, particularly in the thumb subdomain, and an
increased angle of closure in the finger subdomain facili-
tate primer elongation with the unnatural base pair.
Chim et al. recently reported ternary structures of a
hyperthermophilic B-family polymerase, an engineered
KOD mutant, polymerizing TNA [152]. Given the preva-
lent use of B-family hyperthermophiles in polymerase
engineering, the structures of the apo, binary, and tern-
ary polymerase complexes will prove useful in
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sequently published ternary structures of KOD and 9°N
with DNA primer and template and an incoming dNTP
[149, 153] suggest possible explanations for the predis-
position of hyperthermophilic archaeal B-family poly-
merases to engineering: an unusually wide and positively
charged channel between the finger and thumb subdo-
mains may allow space for substrate modifications while
maintaining strong binding to the template and high
processivity. Additionally, whereas the primer template
duplex adopts an A-form in the active site of A-family
polymerases, it adopts a B-form in KOD, possibly con-
tributing to accommodation of nucleotide modifications
in the B-form duplex’s wider major groove.
Rational engineering of XNA polymerases: translation of
mutations across substrates and polymerases
There are numerous examples of transferable mutations
across XNA substrates and polymerases. A recent report
[154] details engineering of a previously described Taq
mutant to better incorporate 2′ modified XNAs. From
kinetic data on incorporation of different 2′ modified
nucleotides, relevant mutations from the literature were
chosen based on the hypothesis that the rate-limiting
step may be recognition of the modified primer strand.
Several mutants showed enhanced synthesis of 2′F and
2′OMe and/or reverse transcription of 2′OMe RNA. In
another instance, diversification at eight “specificity de-
termining residues” selected by computational analysis,
evolutionary conservation, and literature precedent
yielded improved polymerases for RNA and TNA [75].
Furthermore, testing the top mutation sets in the con-
text of different homologous B-family polymerases evi-
denced their general utility as well as revealing the
structural context in which they functioned best. Simi-
larly, polymerase synthesis of increasingly diverse XNAs
was achieved with a TNA polymerase by combining the
TNA sugar with base modifications known to be
polymerase-compatible [31, 32]. While it has been gen-
erally believed that mutation of conserved residues is
highly deleterious, it is becoming increasingly apparent
through this and other work that such mutations can be key
in allowing activity with unnatural substrates [75, 155].
Liu et al. recently reported engineering of a polymer-
ase to synthesize a newly described XNA, tPhoNA, with
both sugar and backbone modifications [33]. Impres-
sively, the polymerase engineering strategy consisted
solely of successive introduction and evaluation of muta-
tions at positions known to affect synthesis for other
XNA substrates. Their success is a testament to the ac-
cumulating knowledge base in the field of polymerase
engineering and the extraordinary ability of a small
number of specific key mutations to confer an expanded
substrate spectrum.RNA polymerases have also been engineered to
synthesize XNAs. It has been shown that T7 RNAP can
transcribe content-expanded RNA from DNA containing
the Ds-Pa UPB as well as further modified Pa bases
[103]. Through a small screen of previously identified
mutations, Kimoto et al. identified a T7 RNAP mutant
that incorporates 2′-F uracil and cytidine triphosphates
and shows improved incorporation of Pa nucleotides
and their analogues in difficult sequence contexts [93].
Surprisingly, several bulky modifications of the Pa nu-
cleotide designed to expand chemical diversity for apta-
mer and ribozyme selections appear to be even better
substrates than the original Pa triphosphates. Similarly, a
Tgo polymerase mutant previously evolved to synthesize
HNA was recently shown to incorporate HNA nucleo-
tides with various aromatic modifications on the uridine
base [35]. Here too, some of the bulkier base modifica-
tions demonstrated superior incorporation.
Reverse transcription of XNAs
Identification of enzymes capable of reverse transcribing
XNAs demonstrates the potential of these divergent
chemistries as genetic materials and is crucial for
in vitro selections [156]. Some XNAs can be reverse
transcribed by natural polymerases (e.g., TNA and
FANA by Bst polymerase [157–159]). Alternately, engin-
eering approaches must be taken [79, 88]. A small num-
ber of mutations in Tgo polymerase yielded a reverse
transcriptase with a generally expanded substrate
spectrum that can reverse transcribe several XNAs to
DNA [29, 78].
Analysis of XNAs and XNA polymerases
One difficulty in working with XNAs is that they are
often incompatible with traditional methods of nucleic
acid manipulation or analysis such as restriction en-
zymes and sequencing technologies. Thus, an important
parallel effort to the development of XNAs and XNA
polymerases is the development of tools to analyze them.
For example, fidelity has not been evaluated in detail for
many of the described XNA polymerases. A recent
method for assaying fidelity reported finding that even
relatively small and natural RNA modifications can sig-
nificantly increase polymerase error rates [160]. Deep se-
quencing has also been used to investigate error profiles
and polymerase read-through of templates with
backbone modifications [161] and found that some com-
monly used isosteric modifications, such as phosphor-
othioates, caused significant copying errors. This fidelity
data foreshadows an important limitation in enzymatic
XNA synthesis that will likely need to be addressed as
the field moves forward. On the other hand, the promis-
cuous behavior of polymerases has been leveraged to
read and record the presence of epigenetic DNA and
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the modifications [162–170]. In addition, the first in-
stance of direct sequencing of an XNA was recently re-
ported; FANA was sequenced using nanopore
technology, albeit with relatively short read lengths
[171].
An XNA particularly limited by a lack of tools is L-
DNA. Such “mirror image” DNA provides both
complete orthogonality in macromolecule-scale features
and interactions, while maintaining identical properties
to DNA at the chemical level. Thus, enzymatic synthesis
of L-DNA requires mirror image polymerases made of
D-amino acids. Zhu and colleagues first made the D-
form of the smallest known polymerase, African Swine
Fever Virus polymerase X, and used it to synthesize L-
DNA, showing that the polymerase was strictly enantio-
specific with no crossover inhibition from D-nucleotide
triphosphates [102]. The group subsequently reported
synthesis of a mutant of the larger thermostable Dpo4
polymerase with D-amino acids, which enabled PCR
amplification of an L-DNA product [99, 100]. Kluss-
mann and colleagues had also reported synthesis of a D-
Dpo4 mutant [101], which was used to assemble gene-
length L-DNA sequences. A mirror image ligase has also
been reported [172]. Mirror image nucleic acids are of
immense interest for therapeutics and are being actively
pursued in research and clinical development [173].
However, their usage remains limited by the arduous
process of synthesizing D-polymerases and the incom-
patibility of L-DNA with traditional nucleic acid ma-
nipulation tools.
Non-natural nucleic acids for therapeutic
applications
Current FDA- and EMA-approved nucleic acid thera-
peutics (Table 2) can be broadly defined in three cat-
egories: antisense (ASO), aptamer, and most recently,
siRNA. Given the inherent instability of natural nucleic
acids in biological fluids, it is not surprising that every
example from these categories is either fully or partly
modified. Fomivirsen, a PS ASO to treat cytomegalovirus
retinitis (CMV), was the first nucleic acid therapeutic to
gain regulatory approval. It was subsequently withdrawn
from the market due to a lack of demand as incidence of
(CMV) infections decreased sharply [184]. Nevertheless,
it proved an important step in demonstrating the safety
and potential of nucleic acid medicines. Eteplirsen and
Golodirsen are fully composed of a morpholino phos-
phoramidate (PMO) backbone, while Mipomersen,
Nusinersen, Inotersen, and Volanesorsen feature both
phosphorothioate (PS) and 2′methoxyethyl (2′MOE)
modifications. Patisiran contains 2′OMe pyrimidine resi-
dues in both siRNA strands. The siRNA Givosiran also
carries PS linkages and 2′F and 2′OMe modifications.Pegaptanib, while discovered as an RNA aptamer, under-
went rounds of medicinal chemistry-like optimization
and modification with 2′OMe and 2′F moieties to in-
crease its in vivo stability and potency. Over 100 oligo-
nucleotide drugs are currently in clinical trials [185],
evidencing the belief and momentum behind these new
therapeutic modalities able to address previously
undruggable target classes.
Somalogic has pioneered aptamer discovery with their
SOMAmer platform [186], which employs modifications
at the C5 position of pyrimidine nucleotides to append
protein-like side chains to aptamer libraries, generating
aptamers of high affinity and specificity for diagnostic
and clinical applications.
As mentioned above, aptamers modified with 2′F and
2′OMe moieties have been selected previously, but Liu
and colleagues have recently made possible direct selec-
tions in the latter backbone at full substitution using two
Taq polymerase variants [104]. Similarly, direct selec-
tions of TNA have recently yielded aptamers against
proteins [187] and small molecule targets [188]. Pursu-
ant to the hypothesis that UBPs increase the sequence
space and thus functional diversity of nucleic acid se-
quences, aptamers containing UBPs have been selected
against both protein targets [189–191] and whole cells
[192, 193].
In many cases, aptamers are selected as DNA or RNA
sequences and then modified post-selection. Commonly,
DNA and RNA aptamers are converted to their 2′ modi-
fied counterparts, producing useful affinity reagents for
applications that would be incompatible with natural nu-
cleic acids (e.g., for stability in alkaline conditions) [194].
In many cases, such post-SELEX modifications decrease
affinity of the original aptamer, arguing for direct selec-
tion in XNA systems where possible. However, this is
not always the case. A single base modification intro-
duced in a thrombin aptamer increased its binding affin-
ity by up to 7-fold [195]. In another recent report,
Sullenger and colleagues modified RNA aptamers
against prostate cancer cells with 2′F pyrimidines. Upon
conjugation with small molecule drugs or therapeutic
peptides, these aptamers displayed significant specificity
and toxicity against cancerous but not normal cells [196,
197]. We direct the reader to a recent review for a more
detailed panorama of modified aptamer chemistry and
related technologies [198].
XNAs are also being explored for other new thera-
peutic modalities beyond siRNA, ASOs, and aptamers.
Modified oligonucleotides capable of cleaving or ligating
other oligonucleotides have been developed as fully
modified “XNAzymes” [156]. In other cases, incorpor-
ation of modified nucleotides at specific positions can
expand chemical functionality or otherwise enhance ca-
talysis [199, 200]. Therapeutic XNAs are also being
Table 2 FDA-approved nucleic acid therapeutics as of February 2020
Drug name
(trade name)
Target Modifications Mechanism Indication Approval Ref.
Fomivirsen
(Vitravene)
mRNA of the CMV
immediate-early (IE)-2
protein
PS ASO
(translation
blocking)
Cytomegalovirus retinitis
(CMV)
FDA (1998) and EMA (1999) approved.
FDA (2001) and EMA (2002) withdrawn
[174]
Pegaptanib
(Macugen)
Vascular endothelial
growth factor (VEGF165)
2′F, 2′OMe, PEG
conjugate
Aptamer Neovascular (wet) age-
related macular
degeneration
FDA approved (2004) [175]
Mipomersen
(Kynamro)
Apolipoprotein B-100
mRNA
2′MOE, PS, 5mC ASO (RNase
H)
Homozygous familial
hypercholesterolemia
FDA approved (2013) [176]
Eteplirsen
(Exondys 51)
Exon 51 in dystrophin
mRNA
PMO ASO
(splicing
modulation)
Duchenne muscular
dystrophy
FDA approved (2016) [177]
Nusinersen
(Spinraza)
Survival of motor
neuron 2 (SMN2) pre-
mRNA
2′MOE, PS, 5mC ASO
(splicing
modulation)
Spinal muscular atrophy FDA (2016) and EMA (2017) approved [178]
Patisiran
(Onpattro)
Transthyretin (TTR)
mRNA
2′OMe siRNA Hereditary transthyretin-
mediated amyloidosis
FDA and EMA approved (2018) [179]
Inotersen
(Tegsedi)
Transthyretin (TTR)
mRNA
2′MOE, PS, 5mC ASO (RNase
H)
Hereditary transthyretin-
mediated amyloidosis
FDA and EMA approved (2018) [180]
Volanesorsen
(Waylivra)
Apolipoprotein C3 (apo-
CIII) mRNA
2′MOE, PS, 5mC ASO (RNase
H)
Familial chylomicronemia
syndrome
EMA approved (2019) [181]
Givosiran
(Givlaari)
Aminolevulinate
synthase 1 (ALAS1)
mRNA
PS, 2′F, 2′OMe,
GalNAc
conjugate
siRNA Acute hepatic porphyria FDA approved (2019) [182]
Golodirsen
(Vyondys 53)
Exon 53 in dystrophin
mRNA
PMO ASO
(splicing
modulation)
Duchenne muscular
dystrophy
FDA approved (2019) [2,
183]
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[202], anti-gene oligonucleotides [203], and CRISPR
guides [204, 205].
Delivery of oligonucleotides into the cytosol of target
cells remains one of the major challengers in the devel-
opment of nucleic acid therapeutics [206, 207]. Conjuga-
tion or encapsulation in lipids has demonstrated
promise in improving pharmacokinetics and biodistribu-
tion [208], and cell-penetrating peptides can increase
transport of biomolecules across cellular membranes
[209, 210]. Other conjugations can enable targeting to
specific tissues with high efficiency; N-acetylgalactosa-
mine (GalNAc) has proven highly efficient for targeting
biomolecules to the liver [211]. However, on the whole,
effective delivery is a major challenge that remains to be
addressed by the field.
The future of unnatural nucleic acid therapeutics
As tools such as XNA polymerases become available for
an increasing number and diversity of nucleic acid
chemistries, it is becoming possible to explore in greater
detail the molecular properties and therapeutic potential
of these unnatural polymers. Several chemistries show
promise in addressing the shortcomings that limit the
utility of natural nucleic acids in therapeutic contexts.
We anticipate that exploration in this field will lead to asteep increase in clinical-stage nucleic acid medicines in
the coming decades.
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